论文部分内容阅读
目的:探讨大剂量沐舒坦联合鼻塞CPAP治疗新生儿肺透明膜病的临床疗效。方法:对26例新生儿肺透明膜病患儿应用大剂量的沐舒坦联合鼻塞CPAP,对治疗结果进行分析。结果:本组26例患儿中,治愈22例,其中,3例气管插管患儿于3～9天后撤机,治愈。死亡2例;放弃治疗2例。结论:大剂量沐舒坦联合鼻塞CPAP治疗新生儿肺透明膜病,临床疗效较好,值得推广。
Objective: To investigate the clinical efficacy of high-dose ambroxol combined with nasal CPAP in the treatment of neonatal hyaline membrane disease. Methods: A total of 26 neonates with hyaline membrane disease were treated with large dose of mucosolvan and nasal CPAP, and the treatment results were analyzed. Results: Twenty-two patients were cured in this group of 26 patients. Among them, 3 patients with tracheal intubation were weaned and cured after 3-9 days. 2 died; give up treatment in 2 cases. CONCLUSION: High-dose ambroxol combined with nasal CPAP in the treatment of neonatal hyaline membrane disease has good clinical efficacy and worthy of promotion.